Prasugrel - Investigational Antiplatelet Agent

The results of the phase III trial showed that treatment with prasugrel was associated with a significant reduction in the composite primary efficacy endpoint as well as in MI, urgent target vessel revascularisation (TVR), and stent thrombosis.


«Back	\|	Next»

Return to Profile